IONS — Completion of Evaluation of Outcome Metrics in Alexander Disease Clinical Trial
Dec 1, 2030, 5:00:00 AM UTC
Summary
The Evaluation of Outcome Metrics in Alexander Disease clinical trial, sponsored by Children's Hospital of Philadelphia, is expected to complete on December 1, 2030. The trial, which began on January 26, 2016, is currently in the recruiting phase and aims to enroll 200 participants. It involves various assessments including physical examinations, therapy evaluations, and questionnaires. While specimen collection is optional, participants are required to return annually for follow-ups. This research is significant as it focuses on assessing metrics for a rare neurological disorder, possibly contributing to better understanding and treatment options for Alexander Disease, which could impact the future operations of companies involved in rare disease pharmacotherapy.
Company
IONIS PHARMACEUTICALS INC (IONS)NASDAQ — Healthcare: Manufacturing, Biotechnology: Pharmaceutical Preparations
www.ionispharma.comSimilar Events
Clinical Trial Completion for NMRA-335140 Evaluation
Neumora Therapeutics, Inc. is set to complete its clinical trial evaluating NMRA-323511, aimed at addressing agitation associated with dementia due to Alzheimer's disease. Titled 'Study to Evaluate the Effects of NMRA-323511 Among Healthy Elderly and Adults,' the trial is designed in two parts: Part A focusing on safety and tolerability in healthy elderly individuals, and Part B assessing efficacy in dementia patients. The study, which involves 96 participants, is anticipated to conclude around December 1, 2025, following a recruitment phase starting July 9, 2024. This trial's outcome could have significant implications for treatment options in this growing patient population.
Clinical TrialExpected Completion of Clinical Trial for DMD Observational Study
Sarepta Therapeutics, Inc. is expected to complete its observational study comparing delandistrogene moxeparvovec with standard care for Duchenne Muscular Dystrophy (DMD) on December 31, 2038. This multicenter, prospective Phase 4 study aims to collect data on treatment outcomes for 500 participants receiving delandistrogene moxeparvovec compared to those prescribed chronic glucocorticoids. The study is currently recruiting, with an anticipated start date of February 7, 2024.
clinical trial completionExpected Completion of Clinical Trial for Auxora in AKI Patients
CalciMedica, Inc. is expecting to conclude a clinical trial for Auxora in patients with acute kidney injury (AKI) by March 1, 2026. Auxora is being investigated for its potential use in treating AKI, which could address a significant unmet medical need. The company is financed, in part, through a new Loan and Security Agreement with Avenue Venture Opportunities, allowing for loans up to $32.5 million, contingent upon achieving certain clinical milestones. Successful completion of the Auxora trial could trigger substantial loan disbursements under the agreement, potentially impacting CalciMedica's financial position and strategic capabilities. The expected milestone achievements can extend interest-only payments and influence further loan tranches. CalciMedica's performance in this trial may therefore have significant business implications regarding financial stability and future drug development initiatives.
Clinical Trial CompletionCompletion of AK006 Clinical Trial
Allakos Inc. is expected to complete the clinical trial for AK006, a drug aimed at assessing its safety, tolerability, pharmacokinetics, and immunogenicity in various cohorts by June 1, 2025. The Phase 1 trial, which kicked off on August 28, 2023, involves 136 participants and includes multiple ascending dose studies in healthy individuals and those with chronic spontaneous urticaria. This trial could potentially validate AK006's therapeutic profile, significantly impacting Allakos' future drug development strategy and market position.
clinical trial completion